In a multivariate analysis, the best predictor for a 12-month progression-free survival upon anti-PD-1 monotherapy involved the quantification of the proximity of PD-L1+ immune cells to tumor cells and the density of intratumoral CD8+ T-cell, as such achieving an AUC of 0.80. The gene discussed is CD8A; the disease is neoplasm.